Open an account

Cue Biopharma

CUE · NASDAQ

$17.04+$0.96 (+5.97%)TodayMarket closed ·
Prev close $16.08

About CUE

Cue Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 29 full-time employees. The company went IPO on 2018-01-02. Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.

Employees
29
Headquarters
Boston, Massachusetts
Listed
Jan 2, 2018
Sector
Health Care
Industry
Biotechnology
Website
cuebiopharma.com

CUE key statistics

Market cap
123.79M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
456.58K
Volume
169.23K
Open price
$15.98
High today
$17.93
Low today
$15.93
52 Week high
$45.50
52 Week low
$4.97

Cue Biopharma (CUE) at a glance

Cue Biopharma (CUE) last traded at $17.04, with a market cap of 123.79M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $15.93 and $17.93. The current price is 7.0% above the day's low and 5.0% below its high.

Volume so far is 169.23K shares, below the average of 456.58K shares a day.

Over the past year Cue Biopharma has ranged from $4.97 to $45.50, and now sits 30% of the way up that range.

Cue Biopharma met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$13.81 per share against an estimate of -$1.71.

The average analyst price target is $89.76, 426.8% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $89.76
Low
$66.66
Now
$17.04
High
$120.75

CUE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 22.4% on average.

  1. Q1 FY24: reported -$7.50 per share against an estimate of -$8.54
  2. Q2 FY24: reported -$6.00 per share against an estimate of -$8.61
  3. Q3 FY24: reported -$5.10 per share against an estimate of -$5.83
  4. Q4 FY24: reported -$3.90 per share against an estimate of -$4.73
  5. Q1 FY25: reported -$5.10 per share against an estimate of -$4.65
  6. Q2 FY25: reported -$2.70 per share against an estimate of -$4.24
  7. Q3 FY25: reported -$2.10 per share against an estimate of -$2.83
  8. Q2 FY26: reported -$13.81 per share against an estimate of -$1.71

CUE news

  • Vandana Singh

    What's Going on With Cue Biopharma Stock on Monday?

  • Press releasePRNewswire

    SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cue Biopharma, Inc. (NASDAQ: CUE)

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • Press releaseGlobe Newswire

    Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Market-Moving News for May 1st

  • Mohd Haider

    Cue Biopharma Stock Surges Over 65% Overnight: Why Is It Moving?

Similar companies

Companies in the same industry as Cue Biopharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.